Panagyurishte

• A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3 … Pending
  2025-523674-16-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• A pivotal clinical study to investigate the safety and efficacy of efimosfermin alfa injection in participants with biopsyconfirmed F2- or F … Pending
  2025-523675-39-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Recruiting
  2025-520565-51-00 5 2026-06-23 small cell lung cancer
• A Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy … Recruiting
  2025-521511-40-00 10 2025-11-18 metastatic non-small cell lung cancer
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 non-small cell lung cancer
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting
  2023-506235-15-00 5 2024-11-07 Limited-Stage Small-Cell Lung Cancer (LS SCLC)
• A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c … Recruiting
  2023-505606-42-00 5 2024-10-15 Head and Neck Squamous Cell Carcinoma (HNSCC)
• A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting
  2023-504247-13-00 4 2023-10-17 Small Cell Lung Cancer
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung … Recruiting
  2024-517780-24-00 5 2025-09-18 Lung Cancer
• Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt … Recruiting
  2024-515698-85-00 5 2025-06-12 Locally Advanced or Metastatic Non-small Cell Lung Cancer
• A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting
  2023-506327-29-00 5 2025-05-14 Non-Small Cell Lung Cancer
• A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn' … Recruiting
  2024-513054-30-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended recruitment
  2024-515538-34-00 10 2025-02-27 Head and Neck Squamous Cell Carcinoma
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph … Ended recruitment
  2023-505989-29-00 5 2024-11-21 Extensive stage small cell lung cancer (ES-SCLC)
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma … Ended recruitment
  2023-503575-21-00 5 2024-01-23 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S … Ended recruitment
  2022-501622-37-00 5 2024-01-16 Multiple Sclerosis

Showing 1–24 of 42 trials